Purdue Pharma’s Avrio Health Launches SlowMag® Mg Calm+Sleep

Purdue Pharma’s Avrio Health Launches SlowMag® Mg Calm+Sleep

Purdue Pharma’s Avrio Health Launches SlowMag® Mg Calm+Sleep

STAMFORD, Conn.–(BUSINESS WIRE)–Avrio Health L.P., a subsidiary of Purdue Pharma L.P., today announced the launch of SlowMag® Mg Calm+Sleep, a dietary supplement with Magnesium Citrate and Melatonin. It supports relaxation, healthy sleep and waking up relaxed.*

SlowMag Mg Calm+Sleep comprises a unique combination of Magnesium and Melatonin that helps your body relax naturally as you drift off to healthy sleep, and promotes a sense of calm and relaxation.* It is formulated with an ideal level of melatonin so you wake up refreshed.* SlowMag Mg tablets are slow to digest. They feature a special enteric coating technology that is designed to reduce the chance of stomach upset. The launch of SlowMag Mg Calm+Sleep is an example of how Avrio Health continues to strengthen its core brand, SlowMag Mg.

This product will be available online and in retail stores this month.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Avrio Health L.P.

Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine®, Colace®, Senokot®, and SlowMag® Mg.

About Purdue Pharma L.P.

Purdue Pharma and its subsidiaries develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers.

The company seeks to achieve a global bankruptcy settlement that would deliver more than $10 billion in value, including 100% of Purdue’s assets and millions of doses of opioid addiction treatment and overdose reversal medicines, to communities across the country to fund programs specifically for abatement of the opioid crisis. The bankruptcy settlement will also deliver funds to private abatement trusts for the benefit of personal injury claimants.

If Purdue’s settlement is approved, Purdue’s assets will be transferred to a new company. This new company will be governed by new independent board members, and will operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company will continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.


Michele Sharp

(203) 585-3195